CD19 and acute lymphoblastic leukemia: We also compared the function of DuAb with that of commercially available bispecific monoclonal antibody, Blincyto, which enables CD3+ T cells to recognize and eliminate CD19+ ALL blasts and has been approved for use in patients with relapsed or refractory B-cell precursor ALL [8].